, using DNA microarrays consisting of 385,000 50-base oligonucleotides that tile 30-million base pairs (bp) at 36 bp resolution. We examined monoand tri-methylation of histone H3 lysine 4 (H3K4me1, H3K4me3) and acetylation of histone H3 lysine 27 (H3K27ac) at well-annotated promoters, reasoning that the state of these histone modifications would vary in a cell-type-specific manner. To our surprise, the chromatin signatures at promoters are remarkably similar across all cell types (Fig. 1a) . Quantitative comparison of ChIP-chip enrichment (see Supplementary Information) revealed highly correlated histone modification patterns at promoters across all cell types, with an average Pearson correlation coefficient of 0.71 ( Supplementary  Fig. 1a ). This observation also holds for the larger set of Gencode promoters ( Supplementary Fig. 2 ).
Next, we identified putative insulators in the ENCODE regions for these cell types based on CTCF binding, because mammalian insulators are generally understood to require CTCF to block promoter2 enhancer interactions 3 . We observed nearly identical CTCF occupancy (Supplementary Table 1 and Supplementary Fig. 1e ) and highly correlated CTCF enrichment patterns across all five cell types ( Supplementary Fig. 1b ), providing experimental support for the mostly cell-type-invariant function of CTCF as suggested by DNase hypersensitivity mapping results 8 . We then investigated transcriptional enhancers in the ENCODE regions, performing ChIP-chip in HeLa, K562 and GM cells to locate binding sites for the transcriptional coactivator protein p300 (Supplementary Tables 224) because p300 is known to localize at enhancers 9 . We observed highly cell-type-specific histone modification patterns at distal p300-binding sites ( Supplementary Fig. 1f ), in marked contrast to the similarities in histone modifications across cell types at promoters. We then used our chromatin-signaturebased prediction method 5 to identify additional enhancers in the ENCODE regions in these cell types (Fig. 1b and Supplementary Tables 529). In addition to the characteristic H3K4me1 enrichment, predicted enhancers are frequently marked by acetylation of H3K27, DNaseI hypersensitivity and/or binding of transcription factors and coactivators, and many contain evolutionarily conserved sequences ( Supplementary Figs 3 and 4 ; see Supplementary Information). Unlike promoters and insulators, but similar to p300-binding sites, the histone modification patterns at predicted enhancers are largely cell-type-specific ( Fig. 1b and Supplementary Fig. 1d ), in agreement with observations that H3K4me1 is distributed in a cell-type-specific manner 10 . These results indicate that enhancers are the most variable class of transcriptional regulatory element between cell types and are probably of primary importance in driving cell-type-specific patterns of gene expression. Knowledge of enhancers is therefore critical for understanding the mechanisms that control cell-type-specific gene expression, yet our incomplete knowledge of enhancers in the human genome has confined previous studies of gene regulatory networks mainly to promoters. To identify enhancers on a genome-wide scale and facilitate global analysis of gene regulatory mechanisms, we performed ChIPchip throughout the entire human genome as described 6 , mapping enrichment patterns of H3K4me1 and H3K4me3 in HeLa cells. Using previously described chromatin signatures for enhancers 5 , we predicted 36,589 enhancers in the HeLa genome ( Fig. 2a and Supplementary Table 10 ; see Supplementary Information). This method correctly located several previously characterized enhancers, including the b-globin HS2 enhancer 11 and distal enhancers for the PAX6 (ref. 12) and PLAT 13 genes (Fig. 2b) . Most predicted enhancers are distal to promoters (Fig. 2c) , have strong evolutionary conservation (see Supplementary Information) and are marked by histone acetylation (H3K27ac), binding of coactivator proteins (p300, MED1) or DNaseI hypersensitivity (DHS) (Fig. 2a, d ; see Supplementary Information). We verified the functional potential of predicted HeLa enhancers using luciferase reporter assays as described 5 (see Supplementary Methods). Out of nine predicted enhancers that we evaluated, seven (78%) were active in reporter assays ( Fig. 2e and Supplementary Table 11), with median activity significantly different from that in random genomic regions (P 5 3.25 3 10
24
). These results support the suitability of using chromatin signatures to identify genomic regions with enhancer function.
We evaluated the predicted enhancers for conserved motif-like sequences using several-hundred shuffled TRANSFAC motifs across ten mammals in a phylogenetic framework that tolerates motif movement, partial motif loss and sequencing or alignment discrepancies (see Supplementary Methods). Predicted enhancers showed conservation for 4.3% of instances (at branch-length-score .50%, see Supplementary Methods), which is substantially greater than for the remaining intergenic regions (2.9%, P , 1 3 10
2100
) and even promoter regions (3.9%, P 5 1 3 10
257
). Additionally, testing a list of 123 unique TRANSFAC motifs as described 14 (see Supplementary Information), we found that 67 (54%) are over-conserved and 39 (32%) are enriched in predicted enhancers (Supplementary Table 12 ). We also performed de novo motif discovery in enhancer regions using multiple alignments of 10 mammalian genomes (see Supplementary Methods), revealing 41 enhancer motifs, 19 of which match known transcription factor motifs whereas 22 are new (Supplementary Table 13 ). These motifs show conservation rates between 7% and 22% in enhancers (median 9.3%), compared to only 1.1% for control shuffled motifs of identical composition. Furthermore, over 90% of these motifs seem to be unique to enhancers, as only 4 motifs are enriched in promoter regions and 12 are in fact depleted in promoters (Supplementary Table  13 ), indicating that predicted enhancers contain unique regulatory sequences that may be specific to enhancer function.
To investigate the association of predicted enhancers with HeLaspecific gene expression, we used Shannon entropy 15 to rank genes by the specificity of their expression levels in HeLa compared to that in three other cell lines (K562, GM06990, IMR90) (Supplementary Fig. 5 ; see Supplementary Information), and then plotted the distribution of enhancers around genes within insulator-delineated domains (as defined by CTCF-binding sites in Supplementary Fig. 6 ; see Supplementary Information). Predicted enhancers are markedly enriched near HeLa-specific expressed genes (Fig. 3a) , particularly within 200 kb of promoters. We observed a 1.83-fold enrichment (P 5 4.71 3 10
2279
) of predicted enhancers around HeLa-specific expressed genes relative to a random distribution (see Supplementary Information) and significant depletion of enhancers around non-specific expressed genes (P 5 5.43 3 10
215
) and HeLa-specific repressed genes (P 5 4.63 3 10
22
). To investigate more directly the relationship between chromatin modification patterns at enhancers and cell-type-specific gene expression, we expanded our global analysis to another cell type. We performed genome-wide ChIP-chip for H3K4me1 and H3K4me3 in K562 cells and identified 24,566 putative enhancers in this cell type using our chromatin-signature-based enhancer-prediction method (Supplementary Table 14 ; see Supplementary Information). invariant whereas those at enhancers are cell-type-specific. We used ChIP-chip to map histone modifications (H3K4me1, H3K4me3 and H3K27ac) in the ENCODE regions in five cell types (HeLa, GM, K562, ES, dES). a, We performed k-means clustering on the chromatin modifications found 65 kb from 414 promoters, and observe them to be generally invariant across cell types. b, As in a, but clustering on 1,423 non-redundant enhancers predicted on the basis of chromatin signatures, revealing the celltype-specificity of enhancers. LogR is the log ratio of enrichment of each marker as determined by ChIP-chip. Promoters and predicted enhancers are located at the centre of 10-kb windows as indicated by black triangles.
Consistent with results in the ENCODE regions, most enhancers predicted in K562 and HeLa cells are unique to either cell type (Fig. 3b) , even though most expressed genes are common between the cell types (Fig. 3c) . Chromatin modification profiles at predicted enhancers throughout the genome are highly cell-type-specific (Fig. 3d) , with a Pearson correlation coefficient of 20.32. Furthermore, these differences seem to have regulatory implications, because domains with HeLa-specific expressed genes are enriched in HeLa enhancers but depleted in K562 enhancers, and vice versa ( Fig. 3e ; see Supplementary Information). These observations hold across all five cell types in the ENCODE regions (see Supplementary Information) . To assess the cell-type-specificity of enhancer activity, we cloned enhancers predicted specifically in K562 cells (and not in HeLa cells) and subjected them to reporter assays in HeLa cells as described above. Out of nine K562-specific enhancers tested, only two (22%) were active in HeLa cells ( Supplementary Fig. 7) , and the median activity of the K-562-specific enhancers was not significantly different from random (P 5 0.11), indicating that the enhancer chromatin signature is a reliable marker of cell-type-specific enhancer function.
Although most enhancers are cell-type-specific, the presence of predicted enhancers shared by HeLa and K562 (Fig. 3b, d) indicates that some enhancers may be active in multiple cell types or conditions. We compared the HeLa enhancer predictions with the results of several genome-wide studies of binding sites for sequence-specific transcription factors in different cell types, namely oestrogen receptor 16 (ER, also known as ESR1), p53 (TP53; ref. 17) and p63 (TP63; ref. 18) in MCF7, HCT116 and ME180 cells, respectively. Interestingly, significant percentages of binding sites for each transcription factor (from 21.4% to 32.6%) overlap with predicted enhancers in HeLa cells (Fig. 4a and Supplementary Table 15) , in contrast to a significant depletion of the repressor NRSF (also known as REST) 19 at predicted enhancers and minimal overlap with CTCFbinding sites (see Supplementary Information) .
To examine the potential role of enhancers in regulating inducible gene expression, we treated HeLa cells with the cytokine interferon-c (IFN-c) and identified binding sites for the transcription factor STAT1 throughout the genome using ChIP-chip. STAT1 generally binds its target DNA sequences only after IFN-c induction 20 , with a small fraction of binding possible before induction 21 . In IFN-c-treated HeLa cells, we identified 1,969 STAT1-binding sites (Supplementary analysis of STAT1 binding in uninduced HeLa cells 21 shows that only 6.5% of IFN-c-induced STAT1-binding sites are occupied by STAT1 before induction. We observed that 429 distal STAT1-binding sites overlapped enhancers predicted in HeLa cells before induction ( Fig. 4a and Supplementary Table 15 ). The H3K4me1 enhancer chromatin signature is present before induction at these STAT1-binding sites, which we designated as STAT1 group I, whereas no evidence of this signature was visible at the remaining 1,260 distal STAT1-binding sites, designated STAT1 group II (Fig. 4b) . Intriguingly, we observed significant relative induction of expression of genes in the domains of STAT1-group-I-binding sites after just 30 min of IFN-c induction, whereas induction levels remained relatively unchanged for genes in the domains of other distal STAT1-group-II-binding sites during this time (Fig. 4c) . These findings indicate that an enhancer chromatin signature confers increased regulatory responsiveness to a STAT1-binding site, in agreement with our previous discovery of functional enhancers in HeLa cells that were marked by the enhancer chromatin signature but were not active until they were bound by STAT1 (ref. 5).
Our findings offer, to our knowledge, the first genome-wide evaluation of the relationship between chromatin modifications at transcriptional enhancers and global programs of cell-type-specific gene expression. We determined over 55,000 potential enhancers in the human genome and show that the chromatin modifications at the are globally related to cell-type-specific gene expression. a, Enhancer localization relative to HeLa-specific expressed genes compared to K562, GM06990 and IMR90 cells (red), nonspecific expressed (green), HeLa-specific repressed (black), and a random distribution (dashed grey). Predicted enhancers are enriched around HeLa-specific expressed genes within insulator-defined domains and depleted in domains of ubiquitous or non-expressed genes (P-value reflects significance of enhancer enrichment in domains of HeLa-specific expressed genes, see Supplementary Information). TSS, transcription start site. enhancers correlate with cell-type-specific gene expression and functional enhancer activity. Perhaps the most intriguing observation is the large number of enhancers identified from the investigation of just two cell lines. Because enhancers are mostly cell-type-specific, our data indicate the existence of a vast number of enhancers in the human genome, on the order of 10 5 210
6
, that are used to drive specific gene expression programs in the 200 cell types of the human body. Future experiments with diverse cell types and experimental conditions will be necessary to comprehensively identify these regulatory elements and understand their roles in the specific gene expression program of each cell type.
METHODS SUMMARY
HeLa, K562 and IMR90 cells were obtained from ATCC. GM06990 cells were acquired from Coriell. All cells were cultured under recommended conditions. Passage 32 H1 cells were cultured as described 22 with/without 200 ng ml 21 BMP4 for 6 days (RND Systems). Chromatin preparation, ChIP, DNA purification and ligation-mediated PCR were performed as described using commercially available and custom-made antibodies, and ChIP samples were hybridized to tiling microarrays and to custom-made condensed enhancer microarrays (NimbleGen Systems, Inc.) as described 5, 6 . DNase-chip was performed and the data analysed as described 23 . Cloning and reporter assays were performed as described 5 . Data were normalized as described 5 , and ChIP-chip targets for CTCF, p300, MED1 and STAT1 were selected with the Mpeak program. We used MA2C (ref. 24 ) to normalize and call peaks on Nimblegen HD2 arrays. Enhancers were predicted, and k-means clustering, intersection analysis and evolutionary conservation analysis were performed as described 5 . Motif analysis was performed as described 25 . Gene expression was analysed using HGU133 Plus 2.0 microarrays (Affymetrix) as described 5 . Specificity of expression was determined using a function of Shannon entropy 15 . We use the MAS5 algorithm from the Bioconductor R package to generate gene expression present/absent calls. Detailed methods can be found in Supplementary Information. Supplementary data for the microarray experiments have been formatted for viewing in the UCSC genome browser via http://bioinformatics-renlab.ucsd.edu/enhancer.
